Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Centessa Pharmaceuticals (CNTA)
NASDAQ:CNTA
RESEARCH TOOLSreports
Centessa Pharmaceuticals (CNTA) Stock Price & Analysis
69 Followers
CNTA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.96 - $12.45
Previous Close$8.79
Volume182.74K
Average Volume (3M)225.90K
Market Cap
$883.24M
Enterprise Value$684.92M
Total Cash (Recent Filing)$281.34M
Total Debt (Recent Filing)$83.02M
Price to Earnings (P/E)-6.2
Beta0.02
Next Earnings
Aug 12, 2024EPS Estimate
-$0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.42
Shares Outstanding113,044,244
10 Day Avg. Volume125,354
30 Day Avg. Volume225,898
Standard Deviation0.18
R-Squared0.17
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)3.94
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.88
Forecast
1Y Price Target
$14.50Price Target Upside64.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Centessa Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial Design AdvantageORX750's innovative trial design promises a swift assessment of wakefulness, potentially accelerating the proof-of-concept phase compared to competitors.
Drug Development ProgressThe FDA cleared ORX750’s IND to initiate Phase 1 trials, marking a significant milestone in the drug’s development pathway.
Financial StabilityCNTA boasts a robust financial foundation, ending the quarter with ample cash reserves to sustain operations well into mid-2026.
Bears Say
Drug EfficacyALKS2680's efficacy may be compromised by saturation of pharmacokinetics at approximately a 15mg dose, potentially limiting its treatment effectiveness.
Drug Safety And Side EffectsTAK-861's requirement for BID dosing and associated common side effects such as frequent urination and insomnia may affect its competitiveness in the market.
Regulatory ConcernsThe FDA's decision on the maximum exposure limit for ORX750, based on convulsions observed in a canine study, could raise concerns about the drug's safety profile.
---
Ownership Overview
27.79% Insiders
6.00% Mutual Funds
53.29% Other Institutional Investors
12.92% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CNTA FAQ
What was Centessa Pharmaceuticals’s price range in the past 12 months?
Centessa Pharmaceuticals lowest stock price was $3.96 and its highest was $12.45 in the past 12 months.
What is Centessa Pharmaceuticals’s market cap?
Currently, no data Available
When is Centessa Pharmaceuticals’s upcoming earnings report date?
Centessa Pharmaceuticals’s upcoming earnings report date is Aug 12, 2024 which is in 88 days.
How were Centessa Pharmaceuticals’s earnings last quarter?
Centessa Pharmaceuticals released its earnings results on May 13, 2024. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.426 by $0.046.
Is Centessa Pharmaceuticals overvalued?
According to Wall Street analysts Centessa Pharmaceuticals’s price is currently Undervalued.
Does Centessa Pharmaceuticals pay dividends?
Centessa Pharmaceuticals does not currently pay dividends.
What is Centessa Pharmaceuticals’s EPS estimate?
Centessa Pharmaceuticals’s EPS estimate is -$0.4.
How many shares outstanding does Centessa Pharmaceuticals have?
Centessa Pharmaceuticals has 113,044,240 shares outstanding.
What happened to Centessa Pharmaceuticals’s price movement after its last earnings report?
Centessa Pharmaceuticals reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.426. Following the earnings report the stock price went up 2.378%.
Which hedge fund is a major shareholder of Centessa Pharmaceuticals?
Among the largest hedge funds holding Centessa Pharmaceuticals’s share is Platinum Investment Management. It holds Centessa Pharmaceuticals’s shares valued at 5M.
---
Centessa Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.50 (64.96% Upside)
$14.50 (64.96% Upside)
Blogger Sentiment
Bullish
CNTA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 113.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 22.4%
Last 30 Days ▼ 22.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
89.43%
12-Months-Change
Fundamentals
Return on Equity
-54.51%
Trailing 12-Months
Asset Growth
-18.74%
Trailing 12-Months
Company Description
Centessa Pharmaceuticals
Centessa Pharmaceuticals PLC is a pharmaceutical company. Its portfolio consists of preclinical to phase 3 uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. Some of its products include Vasopressin V2 Receptor Inhibitor (Lixivaptan), BMP9 Engineered Variant (MGX292), OX2R Agonist (Oral) among others.
---
CNTA Stock 12 Month Forecast
Average Price Target
$14.50
▲(64.96% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Adaptive Biotechnologies
―
BioMarin Pharmaceutical
―
Crispr Therapeutics AG
―
Best Analysts Covering CNTA
1 Year
1 Year Success Rate
9/11 ratings generated profit
1 Year Average Return
+43.12%
reiterated a buy rating 4 days ago
Copying David Risinger's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +43.12% per trade.
---